2nd Pharmaceutical Research Collaborations

Pre-Conference Workshop
Regulatory and Legal Issue Boot camp

Len Smith, Principal Intellectual Property Counsel, 
MEDICIS PHARMACEUTICAL CORPORATION

Chairperson’s Welcome and Opening Remarks

Brian Hubbard, Director Therapeutics Discovery and Development,
BROAD INSTITUTE

KEYNOTE PRESENTATION: How Multi-Disciplinary Research Partnerships Among Different Types of Organizations can be Used to Research Neglected Diseases

Brian Hubbard, Director Therapeutics Discovery and Development, BROAD INSTITUTE

ROLES AND GOALS PANEL DISCUSSION:Understanding the Role of Different Institutions and the Value they Derive from Collaborative Research so You Can Preempt Potential Misunderstandings as Research Proceeds

Moderator
Margaret Cianci, Executive Director,
ALLIANCE FOR CANCER GENE THERAPY

Panelists:
Jeffrey Wasserstein, Senior Vice President, Business Development and Strategy, JOHNSON & JOHNSON

Lita Nelson, Director, Technology Licensing Office,
MASSACHUSETTS INSTITUTE OF TECHNOLOGY

Issi Rozen, Director, Strategic Alliances, BROAD INSTITUTE

SECRETS OF SUCCESSFUL ALLIANCES:What you can do Before Implementing an Alliance, During Startup, and While it’s Ongoing to Increase Operational Efficiency

Mary Lou Bell, Head, Portfolio & Program Management, NIMBUS DISCOVERY

When Established Pharmaceutical Companies Collaborate With Each Other

Leigh Zawel, Executive Director and Oncology Site Lead, MERCK RESEARCH LABS

VENTURE CAPITAL PANEL: Developing a Pharmaceutical Pipeline by Investing in Outside Projects

Moderator:
Amit Srivastava, Project Manager, NOVARTIS INSTITUTE FOR BIOMEDICAL RESEARCH (Invited)

Panelists:
Steven Kuemmerle, Head, Venture Investments, ABBOTT BIOTECH VENTURES

Markus Goebel, Managing Director, NOVARTIS VENTURE FUND 

Chairperson’s Recap of Day One

Brian Hubbard, Director Therapeutics Discovery and Development,
BROAD INSTITUTE

IP CONSIDERATIONS PANEL DISCUSSION, ACADEMIC VERSUS COMMERCIAL: How Universities and Pharma Companies’ IP Policies Differ

Moderator
Marc Malandro, Associate Vice Chancellor for Technology Management and Commercialization, UNIVERSITY OF PITTSBURGH

Panelists
Patrick Zaretski, Esq., Director of Intellectual Property,
CORNERSTONE PHARMACEUTICALS

Jennifer Moitoso, Senior Director, Intellectual Property, SHIRE

John Puziss, Director of Technology Licensing, Office of Cooperative Research, YALE UNIVERSITY

CASE STUDY ON SANOFI’S INNOVATION GRANT SYSTEM: Building an External Innovation Ecosystem by Funding Early and Mid-Stage Collaborations at Leading Universities

Sridrar Natesan, Vice President, External Innovation, SANOFI

CASE STUDY ON PFIZER’S CENTERS FOR THERAPEUTIC INNOVATION (CTIs): Partnering with Universities to Accelerate the Translation of Innovative Discoveries from Bench to Clinic

Anthony Coyle, Vice President/ Chief Science Officer, Centers for Therapeutic Innovation, PFIZER

PRECISION MEDICINE R&D: How Innovative Collaborations help Deliver Differentiated Medicines

Morten Sogaard, Executive Director, Biotherapeutics, PFIZER

POINT COUNTERPOINT: How do Big Pharma and Small Biotechs View Mutual Collaborations?

Small Biotech
Roger Garceau, Senior Vice President, Chief Medical Officer, NPS PHARMACEUTICALS

Big Pharma
Lene Schubert., Associate Director, Project Management,
TAKEDA

Targeting Academic Research with an Eye on Which Therapeutic Areas may be More Likely to Receive Funding from Big Pharma

Nina Green, Director, Office for Technology Licensing and Industry Collaboration, TUFTS UNIVERSITY

MERCK IT INNOVATION CASE STUDY: Using External Innovation to Improve Processes by Bringing in Improvements to Areas Outside of a Pharmaceutical Company’s Core competency

Sanjoy Ray, Director Technology Innovation,
MERCK

How Tech Transfer’s Goals May Differ from Those of Academic Research Departments

Vinit Nijhawan, Managing Director, Technology Development Office Lecturer School of Management & Director Enterprise Programs ITEC,
BOSTON UNIVERSITY